MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481 ·Status: COMPLETED

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965 ·Status: RECRUITING ·Phase: PHASE3

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

NCT01773460 ·Status: TERMINATED ·Phase: PHASE3

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

NCT05996107 ·Status: RECRUITING ·Phase: PHASE1

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751 ·Status: COMPLETED ·Phase: PHASE2

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906 ·Status: RECRUITING ·Phase: PHASE1

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

NCT04394247 ·Status: COMPLETED

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

NCT04740918 ·Status: TERMINATED ·Phase: PHASE3

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

NCT05933395 ·Status: RECRUITING ·Phase: PHASE2

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

NCT05452213 ·Status: RECRUITING ·Phase: PHASE4

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

NCT04055493 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

NCT05501769 ·Status: COMPLETED ·Phase: PHASE1

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146 ·Status: ACTIVE_NOT_RECRUITING

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095 ·Status: RECRUITING ·Phase: PHASE2

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

NCT07330544 ·Status: RECRUITING ·Phase: PHASE2

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

NCT01271725 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00030537 ·Status: COMPLETED ·Phase: PHASE2

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579 ·Status: RECRUITING ·Phase: PHASE1

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

NCT01272141 ·Status: TERMINATED ·Phase: PHASE2

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

NCT06075758 ·Status: COMPLETED

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00574366 ·Status: COMPLETED ·Phase: PHASE1